Retinoic acid–induced survival effects in SH‐SY5Y neuroblastoma cells-Reference-Cited by-同舟云学术

Retinoic acid–induced survival effects in SH‐SY5Y neuroblastoma cells

Published:2018-10-15 Issue:4 Volume:120 Page:5974-5986
ISSN:0730-2312
Container-title:Journal of Cellular Biochemistry
language:en
Short-container-title:J Cell Biochem

Author:

Waetzig Vicki¹^ORCID,Haeusgen Wiebke¹,Andres Cordula¹,Frehse Sonja¹,Reinecke Kirstin¹,Bruckmueller Henrike¹,Boehm Ruwen¹,Herdegen Thomas¹,Cascorbi Ingolf¹

Affiliation:

1. Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig‐Holstein, Campus Kiel Kiel Germany

Funder

Kiel University, Medical Faculty

Publisher

Wiley

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcb.27885

Reference49 articles.

1. Neuroblastoma: Molecular Pathogenesis and Therapy

2. The prenatal origins of cancer

3. The genetic landscape of high-risk neuroblastoma

4. Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation;Peinemann F;Cochrane Database Syst Rev,2017

5. Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia;Oncology Letters;2024-07-04

2. Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models;Frontiers in Oncology;2023-06-13

3. The SH-SY5Y human neuroblastoma cell line, a relevant in vitro cell model for investigating neurotoxicology in human: Focus on organic pollutants;NeuroToxicology;2022-09

4. 4′-Iodo-α-Pyrrolidinononanophenone Provokes Differentiated SH-SY5Y Cell Apoptosis Through Downregulating Nitric Oxide Production and Bcl-2 Expression;Neurotoxicity Research;2022-07-14

5. Genome‑wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor‑resistant CML cells;Oncology Reports;2022-06-22